Advertisements



Flexion Therapeutics: Reversal In Sentiment?

Flexion Therapeutics: Reversal In Sentiment?.....»»

Category: topSource: seekingalphaNov 9th, 2018

Flexion Therapeutics Becomes Oversold (FLXN)

Dividend Channel.....»»

Category: topSource: redinewsApr 13th, 2019

Flexion Therapeutics Inc (FLXN) Q4 2018 Earnings Conference Call Transcript

FLXN earnings call for the period ending December 31, 2018......»»

Category: topSource: foxnewsFeb 28th, 2019

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019

Flexion Therapeutics: Unjustified Selloff In 2018 And Now Undervalued In 2019.....»»

Category: topSource: seekingalphaJan 8th, 2019

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaJan 4th, 2019

First Week of August 16th Options Trading For Flexion Therapeutics (FLXN)

Stock Options Channel.....»»

Category: topSource: redinewsJan 4th, 2019

Flexion Therapeutics" stock tumbles 11% premarket after weak revenue outlook late Thursday

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJan 4th, 2019

Flexion shares plummet after weak revenue guidance

Flexion Therapeutics Inc. shares dove 12% in the extended session Thursday after it released preliminary fourth-quarter revenue and guidance for 2019. The company said it expects fourth-quarter revenue of $9.5 million and full-year revenue o.....»»

Category: topSource: marketwatchJan 3rd, 2019

Raymond James: Flexion Therapeutics Estimates Are A Stretch

Flexion Therapeutics Inc (NASDAQ: FLXN) is scheduled.....»»

Category: blogSource: benzingaJan 3rd, 2019

Oversold Conditions For Flexion Therapeutics (FLXN)

Dividend Channel.....»»

Category: topSource: redinewsDec 21st, 2018

Flexion Therapeutics Stock Sees Short Interest Decline 11%

Market News Video.....»»

Category: topSource: redinewsNov 12th, 2018

Flexion Therapeutics" (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript

Flexion Therapeutics" (FLXN) CEO Michael Clayman on Q3 2018 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaNov 7th, 2018

Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates

Flexion Therapeutics (F.....»»

Category: personnelSource: nytNov 7th, 2018

Commit To Buy Flexion Therapeutics At $12.50, Earn 8.1% Annualized Using Options

Stock Options Channel.....»»

Category: topSource: redinewsSep 24th, 2018

Nomura: Here Are The 3 Signs Stocks Are Becoming Concerned About Excessive Fed Tightening

By Charlie McElligott, head of cross-asset strategy at Nomura Momentum Parties While Softer US Dollar, PBOC Actions Boost Risk-Assets Global risk-sentiment in one asset: Offshore Yuan sees a powerful reversal STRONGER agai.....»»

Category: blogSource: zerohedgeAug 24th, 2018

What Nvidia’s graphics breakthrough means for the company’s stock

Sentiment is bullish on Nvidia’s stock, but any signs of slowing growth could lead to a big reversal......»»

Category: topSource: marketwatchAug 14th, 2018

Flexion Therapeutics (FLXN) Reports Q2 Loss, Lags Revenue Estimates

Flexion Therapeutics (FLXN) d.....»»

Category: worldSource: nytAug 7th, 2018

Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics

Take Advantage Of Poor Market Sentiment And Buy Esperion Therapeutics.....»»

Category: topSource: seekingalphaJul 17th, 2018

Flexion Therapeutics Shares Cross Below 200 DMA

Market News Video.....»»

Category: topSource: redinewsJul 2nd, 2018

Flexion Therapeutics started at buy with $39 stock price target at Benchmark

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchJun 28th, 2018

Biotech Analysis Central Pharma News: Puma"s Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen"s FDA Score

Biotech Analysis Central Pharma News: Puma"s Reversal Win, Pain Therapeutics Suffers Major Blow, Achaogen"s FDA Score.....»»

Category: topSource: seekingalphaJun 27th, 2018